Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Metabolic
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Genzyme snubs offer from Sanofi-Aventis
31 August 2010
After months of speculation Sanofi-Aventis, the French pharma major, at the weekend unveiled an all-cash $69.00 a share bid for Genzyme, which values the US biotech at about $18.5 billion. Not surprisingly, the Genzyme board unanimously rejected the ...
Alogliptin approved for new diabetes combination use in Japan
23 August 2010
Takeda's DPP-4 inhibitor Nesina (alogliptin) has been approved in Japan for the additional indication of concomitant use with thiazolidinedione drugs for the treatment of type 2 diabetes, expanding the range of regimens in which it can be used. In ...
FDA panel to review sibutramine and Arena's lorcaserin for obesity
09 August 2010
The US FDA's endocrinologic and metabolic drugs advisory committee will meet on 15 September to discuss the benefit/risk profile of Abbott's anti-obesity drug sibutramine (Meridia) – and specifically the full study results of the Sibutramine ...
A phoenix rises from the ashes of GSK's Avandia?
30 July 2010
Concerns over the cardiovascular safety of GlaxoSmithKline's diabetes therapy Avandia (rosiglitazone) have generated bad press for the PPARγ agonists of late, but a recent study in Nature suggests that the drug class could be on course for ...
EMA advises switching patients off Genzyme's Fabrazyme because of shortages
09 July 2010
The European Medicines Agency has advised physicians to consider switching patients with Fabry's disease from Genzyme's Fabrazyme (agalsidase beta) onto alternative enzyme replacement therapies such as Shire's Replagal (agalsidase alfa) in light of ...
 
2010 Scrip 100 - Metabolic/endocrinology trials analysis
09 December 2009
disease analysis In the metabolic/endocrinology therapeutic area, 233 industry-sponsored Phase II to Phase III trials were initiated between September 1st, 2008, and August 31st, 2009. Of these, ...
2010 Scrip 100 - Innovate to accumulate
09 December 2009
Drug delivery specialists continue to push the boundaries of innovative science, with recent highlights including the emergence of a needle-free migraine treatment and advances in RNAi delivery, ...
Market Insight - Obesity: what next after the CB1 antagonists' failure?
04 November 2008
The European regulator's recent decision to suspend sales of Sanofi-Aventis 's Acomplia (rimonabant) came hot on the heels of setbacks with two other late-stage CB1 antagonist agents, and the ...
 
GLP-1 receptor agonists vie for diabetes market share
13 July 2010
After enjoying almost five years of exclusivity, Lilly/Amylin's first-in-class antidiabetic GLP-1 receptor analogue Byetta (exenatide) has started to feel competition nipping at its heels. Asher ...
Editorial: Will Acomplia make a comeback?
28 October 2008
Oh what a tangled web of regulation, healthcare policy and ethics the obesity therapy sector has become. The temporary suspension of Sanofi-Aventis 's Acomplia (rimonabant) in the EU because of ...
 
Inhibiting angiotensin type 1 receptors as a target for diabetes
01 October 2008
Background: Angiotensin type 1 (AT1) receptor blockers (ARBs) are used to treat hypertension and related end-organ damage. ARBs have been recognised as regulators of glucose- and lipid metabolism. ...
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
01 July 2008
Background: Sitagliptin is a novel agent forthe treatment of type 2 diabetes either as monotherapy or in combination with metformin or a thiazolidinedione. Objective: To review the efficacy and ...
Pleiotropic effects of thiazolidinediones
01 May 2008
Background: Insulin resistance and hyperglycemia characterize type 2 diabetes mellitus. Type 2 diabetes mellitus is usually accompanied by concomitant disorders, such as dyslipidemia, hypertension ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm